<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04799626</url>
  </required_header>
  <id_info>
    <org_study_id>2021-Antibiotics-009</org_study_id>
    <nct_id>NCT04799626</nct_id>
  </id_info>
  <brief_title>Population Pharmacokinetics and Dosage Individualization of Antibiotics in Elderly Patients</brief_title>
  <official_title>Population Pharmacokinetics and Dosage Individualization of Biapenem,Meropenem,Piperacillin and Tazobactam,Tigecycline in Elderly Patients Who Was Hospitalized in Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Second Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator's purpose is to study the pharmacokinetics and pharmacodynamics of&#xD;
      biapenem,meropenem,piperacillin and tazobactam,tigecycline in elderly ICU patients and&#xD;
      recommend an individual dosage regimen of those antibiotics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of biapenem,meropenem,piperacillin and tazobactam,tigecycline in elderly ICU patients&#xD;
      during clinical treatment depended mostly on experience. Besides, there was no recommended&#xD;
      dose for elderly patients in drug instruction, Therefore, we aim to study the&#xD;
      pharmacokinetics and pharmacodynamics in elderly ICU patients and provide a tailormade&#xD;
      regimen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Days</target_duration>
  <primary_outcome>
    <measure>The peak plasma drug concentration of biapenem,meropenem,piperacillin and tazobactam,tigecycline.</measure>
    <time_frame>at (5-10) minutes after intravenous administration</time_frame>
    <description>To detect the peak plasma drug concentration of biapenem,meropenem,piperacillin and tazobactam,tigecycline after intravenous administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The random plasma drug concentration of biapenem,meropenem,piperacillin and tazobactam,tigecycline.</measure>
    <time_frame>at (0.5-10) hours after intravenous administration</time_frame>
    <description>To detect the random plasma and cerebrospinal fluid drug concentration of biapenem,meropenem,piperacillin and tazobactam,tigecycline after intravenous administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The trough plasma drug concentration of biapenem,meropenem,piperacillin and tazobactam,tigecycline.</measure>
    <time_frame>at 1-2 hours before the next administration</time_frame>
    <description>To detect the trough plasma drug concentration of biapenem,meropenem,piperacillin and tazobactam,tigecycline after intravenous administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-reaction protein</measure>
    <time_frame>Through study completion, an average of 14 days</time_frame>
    <description>Blood routine examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of procalcitonin</measure>
    <time_frame>Through study completion, an average of 14 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Elderly Infection</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <description>The use of antimicrobial agents depends on the clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biapenem,meropenem,piperacillin and tazobactam,tigecycline</intervention_name>
    <description>biapenem,meropenem,piperacillin and tazobactam,tigecycline extended infusion time or continuous infusion for 24 hours;Tigecycline changed standard does for treatment.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Elderly ICU patients (≥65years）treated with biapenem,meropenem,piperacillin and tazobactam&#xD;
        and tigecycline who was hospitalized in the Second Hospital of Shandong University.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) Age ≥65 years old; (2) According to the doctor's advice, use&#xD;
             biapenem,meropenem,piperacillin and tazobactam,tigecycline for anti-infection&#xD;
             treatment;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) Patients who are expected to die within 48 hours; (2) Patients with allergic to&#xD;
             β-lactam antibiotics, Carbapenems, and Ticacycline drugs; (3) Patients receiving other&#xD;
             investigational drugs; (4) Other factors that the researcher considers unsuitable for&#xD;
             inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Zhao, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>The Second Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Zhao, Ph.D</last_name>
    <phone>053188383308</phone>
    <email>zhao4wei2@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wei Zhao</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wei Zhao, Ph.D</last_name>
      <phone>86053188383308</phone>
      <email>zhao4wei2@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 14, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Wei Zhao</investigator_full_name>
    <investigator_title>Head of department of clinical pharmacy and pharmacoligy</investigator_title>
  </responsible_party>
  <keyword>biapenem,meropenem,piperacillin and tazobactam,tigecycline.</keyword>
  <keyword>elderly ICU patients</keyword>
  <keyword>dosage regimen</keyword>
  <keyword>pharmacokinetics and pharmacodynamics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Tigecycline</mesh_term>
    <mesh_term>Biapenem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

